Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey
ConclusionOur findings supported one of the stated benefits of bezafibrate in improving QOL for patients with FAODs.
Source: Molecular Genetics and Metabolism Reports - Category: Genetics & Stem Cells Source Type: research
More News: Clinical Trials | Genetics | Japan Health | Men | Mitochondrial Disease | Pain | Rare Diseases | Study